Reviews/Targeted Therapy Prostate Cancer/Abiraterone overall survival benefit in metastatic hormone-sensitive prostate cancer
Adt Intensify · PC-ADT-01 · v2
Two large, independent randomised trials asked the same question and gave the same answer: adding abiraterone acetate plus a steroid to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer. LATITUDE [5] was blinded and placebo-controlled; STAMPEDE [1] was open-label but much larger, and both found roughly the same size of benefit, a drop in the risk of death of around a third to four tenths. Longer follow-up of the STAMPEDE patients [12][14] showed the benefit lasts for many years, with median survival of 76.6 versus 45.7 months and five-year survival rising from 41% to 60%. A separate real-world cohort [18] pointed in the same direction. The panel placed this at its top tier because two independent trials agree, the benefit is large and durable, and the few caveats (STAMPEDE's open design and its mixed headline population) are offset by LATITUDE's blinded design and STAMPEDE's metastatic-specific analyses.
Two independent randomised trials show a significant overall survival benefit: LATITUDE [5] reports a hazard ratio for death of 0.62 (95% CI 0.51 to 0.76; P<0.001) in newly diagnosed metastatic castration-sensitive disease, and STAMPEDE [1] reports a hazard ratio of 0.63 overall, 0.61 in the metastatic subgroup. Long-term STAMPEDE reports confirm durability: median overall survival 76.6 versus 45.7 months (HR 0.62; P<0.0001) [12], and a metastatic-specific five-year analysis with HR 0.60 and survival rising from 41% to 60% [14]. A real-world Asian cohort [18] found five-year overall survival of 64.9% with ARPI versus 38.7% with ADT monotherapy (ARPI HR 0.41 for overall survival). No disconfirming randomised trial appears in the corpus. The contested point: The only divisions are scope and design: STAMPEDE's headline HR 0.63 [1] pools metastatic and non-metastatic patients (52% metastatic), so the metastatic-specific claim rests on the subgroup HR 0.61 and the metastatic-restricted follow-up [14], and STAMPEDE [1][12][14] is open-label. The real-world cohort [18] measures the ARPI class rather than abiraterone specifically, and [2] found no 2-year OS difference but against bicalutamide with short, unequal follow-up. None of these undercut the OS benefit.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
STAMPEDE's headline OS HR 0.63 [1] pools metastatic and non-metastatic patients (52% metastatic); the claim's metastatic-specific support rests on the subgroup HR 0.61 and the metastatic-restricted follow-up [14], not the primary number.
STAMPEDE [1][12][14] is open-label with no blinding, a risk-of-bias concern; mitigated here because OS is a hard endpoint and the blinded LATITUDE trial [5] shows a near-identical effect.
Where it remains uncertain. STAMPEDE's headline HR pools non-metastatic patients and the trial is open-label [1], but LATITUDE's blinded design [5] and STAMPEDE's metastatic-specific analyses [14] offset both concerns.
Aleatory
LATITUDE's OS result [5] came at a planned interim analysis after 406 deaths with median survival not yet reached, so the point estimate carries sampling uncertainty.
Epistemic
STAMPEDE [1][12][14] had no blinding to treatment allocation, leaving residual bias potential that only LATITUDE's blinded design [5] fully addresses.
Inferential
The supporting real-world benefit [18] is reported for the ARPI class (8.2% of patients received ARPI), not abiraterone specifically, so its transfer to abiraterone alone is an inference.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
STAMPEDE: independent RCT platform; metastatic-subgroup HR 0.61 corroborates LATITUDE in the exact claim population.
“There were 184 deaths in the combination group as compared with 262 in the ADT-alone group (hazard ratio, 0.63; 95% confidence interval [CI], 0.52 to 0.76; P<0.001); the hazard ratio was 0.75 in patients with nonmetastatic disease and 0.61 in those with metastatic disease.”
Panel auditInternal validity: high · scope of inference: Men with locally advanced or metastatic prostate cancer starting long-term ADT; only 52% had metastatic disease so the headline HR mixes metastatic and nonmetastatic patients.Key limitations: population mixes metastatic and nonmetastatic · headline HR not metastatic-only · open-label
LATITUDE: blinded, placebo-controlled RCT in de novo metastatic castration-sensitive disease establishes the OS benefit (HR 0.62).
“the median overall survival was significantly longer in the abiraterone group than in the placebo group (not reached vs. 34.7 months) (hazard ratio for death, 0.62; 95% confidence interval [CI], 0.51 to 0.76; P<0.001)”
Panel auditInternal validity: high · scope of inference: Men with newly diagnosed, metastatic, castration-sensitive (hormone-sensitive) prostate cancer.Key limitations: interim analysis · high-risk mHSPC enrolment criteria
STAMPEDE final analysis confirms the OS benefit is durable beyond 7 years.
“median overall survival was 76·6 months (95% CI 67·8-86·9) in the abiraterone group versus 45·7 months (41·6-52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53-0·73]; p<0·0001)”
Panel auditInternal validity: high · scope of inference: Patients with metastatic prostate cancer starting long-term ADT within STAMPEDE.Key limitations: open-label · standard of care evolved to allow docetaxel mid-trial
The overall survival comparison is abiraterone versus bicalutamide, not versus ADT alone, so it cannot speak to whether adding abiraterone to ADT improves OS.
Panel auditInternal validity: low · scope of inference: Real-world Japanese high-risk mHSPC patients comparing two active ADT-intensification agents.Key limitations: wrong comparator for the claim · retrospective with baseline imbalance · short and unequal follow-up
4 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Two large independent RCTs with concordant ~38% relative mortality reduction, confirmed on long-term follow-up in the exact claim population, place this at the top evidence tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Abiraterone versus other intensification strategies. The claim establishes benefit over ADT alone, but the corpus offers no randomised comparison against docetaxel [4][6] or darolutamide-docetaxel [7][8], leaving sequencing and selection unanswered. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A randomised trial or individual-patient meta-analysis directly comparing ADT plus abiraterone against ADT plus docetaxel in metastatic hormone-sensitive disease.
Open question: Does abiraterone's open-label STAMPEDE survival estimate [1] match what a blinded trial would show? Why it is still open: STAMPEDE [1][12][14] was open-label; only LATITUDE [5] was blinded, and the corpus holds no further blinded confirmation.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19